Insurance & Access · Updated weekly

Will Insurance Cover Obesity Treatment?

It depends on who pays for your plan, the state you live in, and the reason written on the prescription. Start with your type of insurance below. The Medicaid map is rechecked every week, and the date it was last verified is printed on it.

By Doug Maready, MD
Medicaid status checked weekly against state Medicaid notices, budgets, and legislation. Medicare, employer, and self-pay sections current as of October 1, 2026.

Medicaid, today

state Medicaid programs cover GLP-1 medications for obesity, three of them only for severe obesity. 7 states have ended coverage since late 2025.

Last verified Sep 29, 2026

Start Here

What kind of insurance do you have?

Each program follows a different rulebook. Pick yours for the short answer, then read the detail.

65 and older, or disability

Medicare

$50 a month for Wegovy, Zepbound, or Foundayo if you meet the criteria, through December 31, 2027.

Yes, with criteria AHCCCS in Arizona

Medicaid

Decided state by state. 10 states cover obesity medication today. Arizona does not.

Depends on your state Coverage through a job

Employer plan

Your employer decides. Larger employers are more likely to cover these drugs, and some are pulling back.

Ask your plan Healthcare.gov, or no coverage

Marketplace or self-pay

Marketplace plans rarely cover them. Manufacturer cash prices now start around $149 a month.

Usually self-pay

Medicare

A $50 bridge with an end date.

On July 1, 2026, Medicare began paying for obesity medication for the first time. It is a temporary program with specific criteria, not a permanent benefit. Start with the walkthrough, or open a card for the detail.

$50

a month for Wegovy (pen or pill), Zepbound KwikPen, or Foundayo under the Medicare GLP-1 Bridge

BMI 35

qualifies on its own. A lower BMI qualifies only with specific conditions, such as prediabetes or uncontrolled blood pressure

12/31/27

the day the Bridge ends. No Medicare drug coverage for obesity itself is announced after that

Do You Qualify? A Medicare Walkthrough

Eight steps: which route you are on, the BMI grid, the lifestyle requirement, what the pharmacy does, what it costs, and what happens on December 31, 2027.

Open walkthrough

THE FINE PRINT

The Medicare GLP-1 Bridge

Three drugs, a BMI-plus-condition grid, a 72-hour prior authorization, no appeal, and an expiration date.

Read pearls

The Law That Said No

Since 2006 the Part D statute has barred Medicare from paying for weight-loss drugs. It still does. Everything covered today is a workaround.

Read pearls

Counseling Has Been Covered Since 2011

Up to 22 visits a year at no cost, in primary care. Fifteen years in, almost nobody has used it.

Read pearls

Dietitians: Covered, With an Asterisk

A Medicare benefit for diabetes and kidney disease. For obesity alone, the path runs through primary care.

Read pearls

Arizona Obesity Organization · PDF

Bridge Guide for Patients

A one-page walkthrough of who qualifies, what it costs, and what to bring to your visit.

Download the patient guide Arizona Obesity Organization · PDF

Bridge Guide for Clinicians

The provider information sheet: who qualifies, which products are covered, and how the prior authorization works.

Download the clinician guide

Medicaid · Live Tracker

Medicaid, state by state.

Every state covers GLP-1 medications for type 2 diabetes. Covering them for obesity is optional, and each state decides on its own. Tap a state, or tap a color in the legend to highlight that group.

State Medicaid coverage of GLP-1s for obesity

The obesity indication only, in fee-for-service Medicaid. Managed care plans in the same state generally follow the state's drug list.

Last verified Sep 29, 2026

Tap a state. Arizona, for example: AHCCCS covers GLP-1s for type 2 diabetes and Wegovy for cardiovascular risk with prior authorization, but not for obesity itself.

Show every state as a list

Coverage changes with every state budget. Before you rely on this for a prescription, confirm with your state Medicaid agency or your health plan. Prior authorization applies in every state that covers these drugs.

If you live in Arizona

Arizona covers the complications, not the disease.

AHCCCS (Medicaid): No for obesityCovered for type 2 diabetes, and Wegovy for cardiovascular risk with prior authorization.
Medicare: Yes, if you qualifyThe $50 GLP-1 Bridge applies in Arizona like every other state. See the criteria.
State employees: No for weight loss aloneThe state employee plan does not cover any drug solely for weight loss.
The legislature: StalledThe 2025 study committee finished its work. SB 1621, which would have created a permanent obesity council, passed the Senate and died in the House in 2026. The next chance is the 2027 session.

Arizona is not waiting on evidence. It is waiting on a vote.

Arizona Obesity Organization →

Who Flipped

Coverage that switches on and off.

The map shows today. This shows how we got here. Since mid-2024, states have changed their answer 16 times. North Carolina dropped coverage and brought it back ten weeks later. Utah added it for one year.

Medicaid status by month, states that changed

One row per state, one cell per month. Hover or tap a cell for the status that month.

Why switching matters

When coverage stops, treatment stops.

2/3

of the weight lost was regained within a year after people stopped semaglutide, and blood pressure, blood sugar, and cholesterol drifted back toward where they started.

STEP 1 extension. Wilding JPH et al. Diabetes Obes Metab. 2022;24(8):1553-1564.

In a tirzepatide trial, people switched to placebo regained 14 percent of their body weight over the next year, while those who stayed on treatment lost another 5.5 percent.

SURMOUNT-4. Aronne LJ et al. JAMA. 2024;331(1):38-48.

Bottom line

Obesity is a chronic disease. A benefit that turns off every budget cycle pays for the first half of treatment and loses most of what it bought.

Beyond Medication

Counseling, dietitians, and surgery count too.

Medication gets the headlines, but the rest of the treatment ladder is often better covered. Here is what Medicare and Medicaid pay for at each step.

Service	Medicare	Medicaid
ScreeningBMI and counseling referral	Covered BMI recorded at the Annual Wellness Visit. Obesity screening is a USPSTF grade B service, so no cost sharing.	Varies Required for Medicaid expansion adults (USPSTF A and B services) and for children under 21 through EPSDT. Optional in traditional adult Medicaid.
Behavioral therapyIntensive lifestyle counseling	Covered since 2011 Intensive Behavioral Therapy for obesity, BMI 30 or higher, up to 22 visits over 12 months, no copay. Must be furnished in a primary care setting.	Varies Expansion adults get it as a USPSTF B service. Children under 21 get medically necessary counseling through EPSDT. Traditional adult coverage is a state choice.
Dietitian servicesMedical nutrition therapy	Diabetes and CKD Registered dietitians bill Part B for diabetes, non-dialysis kidney disease, and 36 months after kidney transplant. Obesity alone does not qualify. Dietitians can deliver counseling in primary care under supervision.	Varies State option for adults. Most states cover nutrition counseling for children through EPSDT.
Diabetes preventionPrediabetes lifestyle program	Covered since 2018 Medicare Diabetes Prevention Program: prediabetes by lab plus BMI 25 or higher (23 if Asian). Year-long CDC-recognized program, no cost sharing, once per lifetime.	State option Some states cover the National Diabetes Prevention Program for Medicaid adults; many do not.
Obesity medicationGLP-1 and other anti-obesity drugs	Covered, temporarily Medicare GLP-1 Bridge through December 31, 2027, if you meet the criteria. Separately, Part D covers these drugs for type 2 diabetes, cardiovascular risk, sleep apnea, and MASH.	10 states Every state covers GLP-1s for type 2 diabetes. For obesity itself, 10 states cover them today. See the map.
Bariatric surgeryGastric bypass, sleeve, and others	Covered BMI 35 or higher, at least one obesity-related condition, and prior unsuccessful medical treatment. Bypass, sleeve, duodenal switch, and adjustable band.	Most states Some form of coverage in 48 states as of the 2022 Obesity Across America report. Criteria and waiting periods vary widely.
Health coachingIndividual and group	Proposed for 2027 The 2027 Medicare fee schedule proposal would pay nationally for health and well-being coaching, individual and group. The final rule is expected in November 2026.	Not standard Available only where a state or managed care plan adds it.

ON THE HORIZON

What Could Change in 2027

Paid health coaching in Medicare, Louisiana's scheduled expansion, the January 1 deadline for states to join the BALANCE model, and the Treat and Reduce Obesity Act.

Read pearls

Insurance Through a Job

Your employer decides.

Most people with private insurance get it through work, and the employer chooses whether obesity medication is in the plan. Bigger employers are more likely to say yes. Some are reversing course because of cost.

43%

of firms with 5,000 or more workers covered GLP-1s for weight loss in 2025, up from 28% in 2024. Only 16% of firms with 200 to 999 workers did. KFF Employer Health Benefits Survey, 2025

36%

of employers surveyed in 2026 covered them for weight loss, about the same as 2025. 60% covered them for diabetes only. IFEBP, July 2026

72% → 60%

Share of large employers covering them for weight loss, 2025 to 2026. Business Group on Health, 2027 Employer Healthcare Strategy Survey

Public employers are pulling back too

Arizona: the state employee plan does not cover any drug solely for weight loss. Covering obesity was estimated at about $31 million a year (Joint Legislative Budget Committee, November 2025).
North Carolina: the State Health Plan ended weight-loss coverage in April 2024 and has not restored it.
Massachusetts: the state employee insurance board voted in February 2026 to end weight-loss coverage starting with the July 2026 plan year.

Even when obesity is excluded, the same drugs may be covered for type 2 diabetes, cardiovascular risk, sleep apnea, or MASH. Ask about each one.

Questions to ask HR or your plan

Are anti-obesity medications covered, or listed as an exclusion in the plan documents?
If covered: what BMI, what prior authorization, and what weight loss is needed to stay on it?
Is a specific lifestyle or coaching program required first?
Is Wegovy covered for heart disease, or Zepbound for sleep apnea, even if obesity is excluded?
Is bariatric surgery a covered benefit, and at which centers?
Are dietitian and obesity counseling visits covered? Most plans must cover obesity counseling at no cost under the ACA preventive services rules.

Marketplace and Self-Pay

When insurance says no.

Marketplace plans from Healthcare.gov almost never cover obesity medication. North Dakota is the only state whose required benefit package includes it, for severe obesity, since 2025. For most people without coverage, the realistic path is buying directly from the manufacturer.

Medication	Form	Self-pay per month	Where
Wegovysemaglutide	Pill	$149 to $299	NovoCare Pharmacy. Price rises with the dose.
Wegovysemaglutide	Weekly pen	$199 to $349	NovoCare Pharmacy. Starting doses are $199 through December 31, 2026, then $349. The 7.2 mg dose is $399.
Zepboundtirzepatide	Vial or KwikPen	$299 to $449	LillyDirect. Higher doses keep the lower price only with on-time refills.
Foundayoorforglipron	Daily pill	$149 to $299	LillyDirect. Some introductory prices end December 31, 2026.

Manufacturer cash prices as listed October 1, 2026. They change often; check the manufacturer site before you fill. Self-pay purchases usually do not count toward your insurance deductible. Compounded versions are not FDA-approved products.

How this page stays current

Every Monday the state-by-state Medicaid status is rechecked against state Medicaid agency notices, prior authorization forms, budgets, and legislation, with KFF and other trackers as cross-checks. When a state's status changes, the map, the counts, and the timeline update together, and the "last verified" date moves forward.

This page covers the obesity indication in fee-for-service Medicaid. A state can cover the same drugs for diabetes, heart disease, sleep apnea, or liver disease and still appear here as not covering obesity.

The Law That Said No

For twenty years Medicare paid for the heart attacks, the dialysis, and the joint replacements, but not the treatment upstream. One clause explains it.

Since Part D began in 2006, the statute has excluded "agents when used for weight loss" from coverage, borrowing the same exclusion list Medicaid has used since 1990.
The exclusion is about the indication, not the molecule. Part D covers semaglutide and tirzepatide when prescribed for type 2 diabetes (Ozempic, Mounjaro).
Each new label opened a door: Wegovy for cardiovascular risk reduction (March 2024), Zepbound for obstructive sleep apnea (December 2024), Wegovy for MASH (August 2025).
In November 2024 CMS proposed reinterpreting the exclusion so obesity treatment would count as treating a chronic disease. The final rule in April 2025 dropped it.
The workaround is demonstration authority. The GLP-1 Bridge runs outside Part D, funded and administered by CMS directly, so no plan carries risk and the statute is not touched.
Part D's $2,100 out-of-pocket cap for 2026 applies to the comorbidity route. Bridge copays sit outside Part D and do not count toward it.
The November 2025 manufacturer pricing agreements are the financial floor under both the Bridge and the BALANCE Model.

Bottom line

The exclusion is still law. Everything Medicare covers for obesity itself today is either a comorbidity indication or a time-limited demonstration. The question for a patient is not "is it covered" but "which route do I qualify for."

References

Social Security Act §1860D-2(e)(2)(A), incorporating §1927(d)(2)(A).

CMS. Contract Year 2026 Policy and Technical Changes to Medicare Advantage and Part D. Proposed November 2024; final rule April 2025.

KFF. What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries. 2026.

FDA prescribing information: Wegovy (2024, 2025), Zepbound (2024).

Medicare

The Medicare GLP-1 Bridge

A national demonstration, not a Part D benefit. Real, narrower than the FDA label, and dated.

Runs July 1, 2026 through December 31, 2027. The original end date of December 31, 2026 was extended in spring 2026.
$50 per prescription for Foundayo (orforglipron), Wegovy (injection and tablets), and Zepbound in the KwikPen only. Zepbound vials and single-dose pens are not included.
Tier 1: BMI 35 or higher, no comorbidity needed. Tier 2: BMI 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension (above 140/90 on two or more drugs), or CKD stage 3a or worse. Tier 3: BMI 27 or higher plus prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
Age 18 and older. Type 2 diabetes, moderate-to-severe sleep apnea, and noncirrhotic MASH are excluded because Part D already covers those indications.
Must be prescribed with current and ongoing lifestyle modification including structured nutrition and physical activity. The prescriber attests under penalty of perjury.
The pharmacy submits the claim first, then the prescriber completes prior authorization. Decisions within 72 hours. There is no appeal, only resubmission with corrected information.
The $50 does not count toward the Part D deductible or the $2,100 out-of-pocket cap.
KFF estimates about 3.8 million beneficiaries met the criteria in 2023, roughly 8 percent of Part D enrollees.

Bottom line

Bring the numbers to the visit. Eligibility is a grid of BMI against blood pressure, kidney function, A1c, and cardiovascular history, and a patient with BMI 32 and nothing on the list does not qualify even though the FDA label says otherwise.

Arizona Obesity Organization guides (PDF): for patients and for clinicians.

References

CMS. Medicare GLP-1 Bridge: Information for Providers. Updated August 6, 2026.

CMS. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month. Product 12234. 2026.

KFF. Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge. July 2026.

Medicare Rights Center. GLP-1 Weight-Loss Drug Demonstration Begins July 2026. June 4, 2026.

Behavioral Therapy

Counseling Has Been Covered Since 2011

Medicare's oldest obesity benefit is also its least used. The Bridge's lifestyle requirement gives it a second life.

National Coverage Determination 210.12, effective November 29, 2011: Intensive Behavioral Therapy for obesity, BMI 30 or higher, no copay, no deductible.
Schedule: weekly in month 1, every other week in months 2 through 6, then monthly in months 7 through 12 for patients who have lost at least 3 kg by month 6. Up to 22 visits a year.
Must be furnished by a primary care physician or practitioner in a primary care setting. Specialty clinics cannot bill it, and dietitians cannot bill it directly.
Dietitians, nurses, and other auxiliary staff can deliver the sessions in primary care under practitioner supervision, billed by the practice.
Codes: G0447, individual, 15 minutes. G0473, group of 2 to 10, 30 minutes, added in 2015. Group visits are already covered.
Content follows the 5 A's: assess, advise, agree, assist, arrange.
Uptake in the benefit's first four years was under one percent of beneficiaries with obesity: 3.5 to 7.3 per 1,000 from 2012 to 2015. The primary care restriction and the 15-minute unit are the usual explanations.
Two companion benefits: BMI at the Annual Wellness Visit, and the Medicare Diabetes Prevention Program since 2018 for prediabetes with BMI 25 or higher.

Bottom line

Coverage was never the barrier for counseling. The delivery rules were. The Bridge requires documented, ongoing lifestyle modification, and IBT in primary care is the covered way to deliver and document it.

References

CMS. National Coverage Determination 210.12, Intensive Behavioral Therapy for Obesity. Decision memo CAG-00423N. November 2011.

Noridian Medicare. Intensive Behavioral Therapy (IBT) for Obesity, JE and JF Part B. 2026.

Dewar S, Bynum J, Batsis JA. J Gen Intern Med. 2020;35(1):368-370.

CMS. Medicare Diabetes Prevention Program Expanded Model. 2018.

Nutrition Services

Dietitians: Covered, With an Asterisk

A registered dietitian is a Medicare-covered provider. Whether obesity gets you in the door depends on what else is on the problem list.

Medical nutrition therapy has been a Part B benefit since 2002. Registered dietitians bill it directly for diabetes, non-dialysis chronic kidney disease, and 36 months after a kidney transplant.
3 hours in the first year, 2 hours each year after, more with a physician referral for a change in condition. No cost sharing.
Obesity alone is not a covered MNT diagnosis. Neither is prediabetes.
The overlap is real: Bridge tier 2 includes CKD stage 3a or worse, which does qualify for MNT. Patients on the diabetes route qualify too.
For obesity without those diagnoses, the dietitian reaches the patient through IBT in primary care, delivered under practitioner supervision, or through a Medicare Advantage supplemental benefit.
The Medical Nutrition Therapy Act (H.R. 6199 and S. 3934, 119th Congress) would extend MNT to obesity, prediabetes, hypertension, and other conditions. Introduced, not passed.
The CY 2027 fee schedule proposal would make MNT and diabetes self-management training stand-alone billable visits in Rural Health Clinics, matching FQHCs.

Bottom line

Dietitian services are covered by Medicare when a diabetes or kidney diagnosis is attached, and reachable through primary care for obesity itself. The clean, direct obesity nutrition benefit is still a bill in Congress.

References

Social Security Act §1861(vv); 42 CFR 410.130-410.134.

Medicare.gov. Nutrition therapy services. 2026.

H.R. 6199, Medical Nutrition Therapy Act of 2025; S. 3934, Medical Nutrition Therapy Act of 2026. 119th Congress.

CMS. Calendar Year 2027 Medicare Physician Fee Schedule Proposed Rule, fact sheet. July 2026.

On the Horizon

What Could Change in 2027

Four dates and decisions to watch. None of them is final until it happens.

Medicare health coaching. The 2027 Physician Fee Schedule proposal would pay nationally for health and well-being coaching (CPT 0591T and 0592T individual, 0593T group) under a Medicare practitioner. Comments closed September 14, 2026. The final rule usually arrives in early November and would take effect January 1, 2027.
BALANCE model deadline. States can join the Medicaid track of the federal BALANCE model through January 1, 2027. It offers a negotiated price and a manufacturer-funded lifestyle program and runs through 2031. Indiana announced it will join; CMS has not yet named participating states. The Medicare half of BALANCE was delayed indefinitely in April 2026.
Louisiana. A 2026 law expands Medicaid coverage to adults with BMI 35 or higher, or 30 or higher with prediabetes, hypertension, or heart disease, starting January 1, 2027. Funding has not been identified.
Arizona. The 2027 legislative session is the next chance to recognize obesity as a chronic disease and revisit AHCCCS coverage.
Congress. The Treat and Reduce Obesity Act (H.R. 4231 and S. 1973) would let Medicare Part D cover obesity medication permanently. Versions have been introduced in every Congress since 2012, and none has passed.
The Bridge ends December 31, 2027. Without new law or a revived Part D model, Medicare drug coverage for obesity itself ends with it.

Bottom line

2027 could add coaching to Medicare and new states to Medicaid. Permanent Medicare drug coverage for obesity still requires Congress.

References

CMS. Calendar Year 2027 Medicare Physician Fee Schedule Proposed Rule, fact sheet. July 2026.

CMS Innovation Center. BALANCE Model. Page modified September 29, 2026.

Indiana Capital Chronicle. Indiana Medicaid will cover GLP-1s for obesity. July 30, 2026.

Louisiana SB 433 (2026); American Diabetes Association press release, June 16, 2026.

H.R. 4231 and S. 1973, Treat and Reduce Obesity Act of 2025. 119th Congress.

Military and Veterans

TRICARE and the VA

Two federal systems, two sets of rules, and one group that fell through the gap.

TRICARE Prime and TRICARE Select cover GLP-1 medications for weight management with prior authorization.
TRICARE For Life stopped covering them for weight loss on August 31, 2025. Diabetes coverage continues on every TRICARE plan.
Most TRICARE For Life members do not have a Medicare Part D plan, so they cannot use the Medicare GLP-1 Bridge either. Military associations are pressing Congress to close that gap.
The VA treats Wegovy and Zepbound as non-formulary drugs that need clinical justification. Typical criteria are BMI 30 or higher with a weight-related condition and recent participation in MOVE!, the VA's weight management program.
Veterans who also have Medicare and a Part D plan may qualify for the Bridge outside the VA.

Bottom line

If you are on TRICARE For Life, ask whether adding a Part D plan would make you eligible for the $50 Bridge. If you use the VA, start with MOVE!; it is usually the first requirement.

References

MOAA. Summer AIA 2026: Fighting for TRICARE For Life Beneficiaries Left Behind. July 27, 2026.

VA Pharmacy Benefits Management. Criteria for use, weight management medications. 2026.

Will Insurance Cover Obesity Treatment?

What kind of insurance do you have?

Medicare

Medicaid

Employer plan

Marketplace or self-pay

TRICARE or VA

A $50 bridge with an end date.

Do You Qualify? A Medicare Walkthrough

The Medicare GLP-1 Bridge

The Law That Said No

Counseling Has Been Covered Since 2011

Dietitians: Covered, With an Asterisk

Bridge Guide for Patients

Bridge Guide for Clinicians

Medicaid, state by state.

State Medicaid coverage of GLP-1s for obesity

Coverage that switches on and off.

Medicaid status by month, states that changed

When coverage stops, treatment stops.

Counseling, dietitians, and surgery count too.

What Could Change in 2027

Your employer decides.

Public employers are pulling back too

Questions to ask HR or your plan

When insurance says no.

How this page stays current

See also

Do You Qualify? A Medicare Walkthrough

01Confirm You Have Medicare Drug Coverage

02Check the Diagnoses Part D Already Covers

03Find Your Tier on the Bridge Grid

04Put the Lifestyle Program on Paper

05Understand What the Pharmacy Does

06Know the Real Cost

07Do Not Forget Surgery

08Mark December 31, 2027